A CRA expert was retained to analyze class certification issues relating to allegations that a pharmaceutical product was marketed for off-label uses and caused direct and indirect purchasers to pay for billions of dollars unnecessarily. The expert found that differences among putative class members would necessitate individualized inquiries into whether the alleged conduct caused each any economic damages. The judge denied class certification, citing the CRA expert’s opinion in support of several key points.
Navigating private equity in health care amid regulatory scrutiny
She joined Leslie C. Overton from Axinn Veltrop & Harkrider LLP and Rebekah Goshorn Jurata of the American Investment Council to discuss the growing antitrust...